# DVA

**Deep-research report — K3vl4r**  
**Symbols:** DVA  
**Sources:** 29  
**Published:** 2026-08-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-dva-1423

---

# DaVita (DVA) Research Brief — As of August 3, 2026

## Overview

DaVita Inc. is a leading U.S. provider of kidney dialysis services, operating within a domestic duopoly and serving approximately 296,300 patients across 3,262 outpatient dialysis centers globally as of March 31, 2026 [[17]](https://investors.davita.com/). The company generates the vast majority of its revenue through per-treatment reimbursements from commercial insurers and government programs (Medicare/Medicaid), supplemented by its growing Integrated Kidney Care (IKC) segment [[4]](https://markets.financialcontent.com/dailynews/article/finterra-2026-2-11-the-dialysis-renaissance-how-davita-dva-conquered-the-glp-1-fear-and-defined-healthcare-resilience-in-2026).

---

## Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-dva-1423 (free to sign up)._